| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Biotest AG (ETR: BIO)
BIO Technical Analysis
2
| As on 1st Nov 2017 BIO Share Price closed @ 24.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 24.15 & Strong Sell for SHORT-TERM with Stoploss of 28.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIO Share Price
| Open | 25.00 | Change | Price | % |
| High | 25.06 | 1 Day | -3.18 | -11.41 |
| Low | 23.70 | 1 Week | 0.00 | 0.00 |
| Close | 24.70 | 1 Month | -3.50 | -12.41 |
| Volume | 8509 | 1 Year | 7.50 | 43.60 |
| 52 Week High 29.09 | 52 Week Low 15.70 | ||||
ETR Germany Most Active Stocks
| DTE | 15.31 | -2.11% |
| DBK | 14.13 | 1.29% |
| EOAN | 10.38 | 2.47% |
| CBK | 11.88 | 0.93% |
| IFX | 24.51 | 4.30% |
| LHA | 28.21 | 2.96% |
| DAI | 73.07 | 2.50% |
| BIR | 0.24 | 0.00% |
| TKA | 23.49 | 2.53% |
| MEO | 29.18 | 0.00% |
ETR Germany Top Gainers Stocks
ETR Germany Top Losers Stocks
| BIO Daily Charts |
BIO Intraday Charts |
Whats New @ Bazaartrend |
BIO Free Analysis |
|
|
BIO Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 25.96 |
| RESISTANCE | 25.44 |
| SUPPORT | 23.96 |
| SUPPORT | 23.44 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
BIO Target for Month September
| 4th UP TARGET | 30.91 |
| 3rd UP TARGET | 29.94 |
| 2nd UP TARGET | 29.34 |
| 1st UP TARGET | 28.74 |
| 1st DOWN TARGET | 27.02 |
| 2nd DOWN TARGET | 26.42 |
| 3rd DOWN TARGET | 25.82 |
| 4th DOWN TARGET | 24.85 |
BIO Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
BIO Target for Year 2020
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Biotest AG ( ETR Germany Symbol : BIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
